Literature DB >> 19533148

Pain after uterine fibroid embolisation is associated with the severity of myometrial ischaemia on magnetic resonance imaging.

Anu Ruuskanen1, Petri Sipola, Maritta Hippeläinen, Marion Wüstefeld, Hannu Manninen.   

Abstract

The purpose of the study was to evaluate uterine ischaemia after uterine artery embolisation (UAE) using magnetic resonance imaging and the role of myometrial and fibroid ischaemia in the pathogenesis of post-procedural pain. T1-weighted gradient echo imaging before and after contrast agent was performed on 62 women before and 24 h after UAE. We assessed the severity (mild, moderate, severe) of myometrial ischaemia, and the percentage and volume of ischaemic tissue in myometrium and fibroids. The Verbal Rating Scale was used to assess in-hospital post-procedural pain (1-3 mild, 4-6 moderate, 7-10 severe). Mean maximal pain was 7.7. Myometrial ischaemia was mild, moderate and severe in 29, 23 and 10 patients, respectively. Moderate or severe myometrial ischaemia (p = 0.041), the percentage (p = 0.037) and volume (p = 0.012) of ischaemic tissue in the myometrium, and a large volume of embolic material (p = 0.038) correlated with severe pain. In summary, pain following UAE is common and partly explained by myometrial ischaemia.

Entities:  

Mesh:

Year:  2009        PMID: 19533148     DOI: 10.1007/s00330-009-1481-8

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  29 in total

1.  A comparison of chemoembolization endpoints using angiographic versus transcatheter intraarterial perfusion/MR imaging monitoring.

Authors:  Robert J Lewandowski; Dingxin Wang; James Gehl; Bassel Atassi; Robert K Ryu; Kent Sato; Albert A Nemcek; Frank H Miller; Mary F Mulcahy; Laura Kulik; Andrew C Larson; Riad Salem; Reed A Omary
Journal:  J Vasc Interv Radiol       Date:  2007-10       Impact factor: 3.464

2.  Pain after uterine artery embolization for leiomyomata: can its severity be predicted and does severity predict outcome?

Authors:  A R Roth; J B Spies; S M Walsh; B J Wood; J Gomez-Jorge; E B Levy
Journal:  J Vasc Interv Radiol       Date:  2000-09       Impact factor: 3.464

Review 3.  Pain: a review of three commonly used pain rating scales.

Authors:  Amelia Williamson; Barbara Hoggart
Journal:  J Clin Nurs       Date:  2005-08       Impact factor: 3.036

4.  Uterine artery embolization in the treatment of symptomatic uterine fibroid tumors (EMMY trial): periprocedural results and complications.

Authors:  Nicole A Volkers; Wouter J K Hehenkamp; Erwin Birnie; Cees de Vries; Cor Holt; Willem M Ankum; Jim A Reekers
Journal:  J Vasc Interv Radiol       Date:  2006-03       Impact factor: 3.464

5.  Uterine artery embolization for the treatment of uterine leiomyomata midterm results.

Authors:  S C Goodwin; B McLucas; M Lee; G Chen; R Perrella; S Vedantham; S Muir; A Lai; J W Sayre; M DeLeon
Journal:  J Vasc Interv Radiol       Date:  1999-10       Impact factor: 3.464

6.  Long-term outcome from uterine fibroid embolization with tris-acryl gelatin microspheres: results of a multicenter study.

Authors:  James B Spies; Curt Cornell; Robert Worthington-Kirsch; John C Lipman; James F Benenati
Journal:  J Vasc Interv Radiol       Date:  2007-02       Impact factor: 3.464

7.  Symptomatic fibroleiomyomata: MR imaging of the uterus before and after uterine arterial embolization.

Authors:  R C Jha; S M Ascher; I Imaoka; J B Spies
Journal:  Radiology       Date:  2000-10       Impact factor: 11.105

8.  Tolerance, hospital stay, and recovery after uterine artery embolization for fibroids: the Ontario Uterine Fibroid Embolization Trial.

Authors:  Gaylene Pron; Eva Mocarski; John Bennett; George Vilos; Andrew Common; Mukarram Zaidi; Kenneth Sniderman; Murray Asch; Roman Kozak; Martin Simons; Cuong Tran; John Kachura
Journal:  J Vasc Interv Radiol       Date:  2003-10       Impact factor: 3.464

9.  The Ontario Uterine Fibroid Embolization Trial. Part 2. Uterine fibroid reduction and symptom relief after uterine artery embolization for fibroids.

Authors:  Gaylene Pron; John Bennett; Andrew Common; Jane Wall; Murray Asch; Kenneth Sniderman
Journal:  Fertil Steril       Date:  2003-01       Impact factor: 7.329

10.  Uterine artery embolization versus hysterectomy in the treatment of symptomatic uterine fibroids: 2 years' outcome from the randomized EMMY trial.

Authors:  Nicole A Volkers; Wouter J K Hehenkamp; Erwin Birnie; Willem M Ankum; Jim A Reekers
Journal:  Am J Obstet Gynecol       Date:  2007-06       Impact factor: 8.661

View more
  5 in total

1.  Uterine artery embolisation versus hysterectomy for leiomyomas: primary and 2-year follow-up results of a randomised prospective clinical trial.

Authors:  Anu Ruuskanen; Maritta Hippeläinen; Petri Sipola; Hannu Manninen
Journal:  Eur Radiol       Date:  2010-06-06       Impact factor: 5.315

Review 2.  Clinical and periprocedural pain management for uterine artery embolization.

Authors:  Elizabeth Brooke Spencer; Peter Stratil; Heidi Mizones
Journal:  Semin Intervent Radiol       Date:  2013-12       Impact factor: 1.513

3.  Diffusion-weighted MR imaging of uterine leiomyomas following uterine artery embolization.

Authors:  Olivier Sutter; Philippe Soyer; Eimad Shotar; Raphael Dautry; Youcef Guerrache; Vinciane Placé; Raluca Opréa; Aude Ricbourg; Olivier Le Dref; Mourad Boudiaf; Marc Sirol; Anthony Dohan
Journal:  Eur Radiol       Date:  2016-01-22       Impact factor: 5.315

Review 4.  Cross-sectional imaging of acute gynaecologic disorders: CT and MRI findings with differential diagnosis-part II: uterine emergencies and pelvic inflammatory disease.

Authors:  Pietro Valerio Foti; Massimo Tonolini; Valeria Costanzo; Luca Mammino; Stefano Palmucci; Antonio Cianci; Giovanni Carlo Ettorre; Antonio Basile
Journal:  Insights Imaging       Date:  2019-12-20

5.  Can pre-procedural MRI signal intensity ratio predict the success of uterine artery embolization in treatment of myomas?

Authors:  Çağlayan Çakır; Fatih Kılınç; Muhammed Akif Deniz; Sema Karakaş
Journal:  Turk J Med Sci       Date:  2021-06-28       Impact factor: 0.973

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.